Research programme: ion channel and GABA A modulators - Saniona
Alternative Names: AN 346; AN 363; AN 470; AN 761; AN-726; NS9283; NSD-708; NSD-761; NSD-847; NSD-867Latest Information Update: 02 Oct 2021
At a glance
- Originator GlaxoSmithKline; NeuroSearch
- Developer Saniona
- Class Analgesics; Anti-inflammatories; Antidementias; Antipruritics; Neuroprotectants
- Mechanism of Action Alpha4beta2 nicotinic receptor modulators; Alpha7 nicotinic acetylcholine receptor agonists; GABA A alpha 2 receptor modulators; GABA A alpha 3 receptor modulators; GABA A receptor modulators; GABA modulators; Intermediate conductance calcium activated potassium channel modulators; Ion channel modulators; Small-conductance calcium-activated potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; CNS disorders; Dyskinesias; Inflammatory bowel diseases; Neuropathic pain; Schizophrenia
Most Recent Events
- 28 Feb 2020 Discontinued - Preclinical for Alzheimer's disease in Denmark (unspecified route)
- 28 Feb 2020 Discontinued - Preclinical for CNS disorders in Denmark (unspecified route)
- 28 Feb 2020 Discontinued - Preclinical for Dyskinesias in Denmark (unspecified route)